Cargando…

Bridging the Gap between AZF Microdeletions and Karyotype: Twelve Years’ Experience of an Infertility Center

PURPOSE: Despite all past efforts, the current guidelines are not explicit enough regarding the indications for performing azoospermia factor (AZF) screening and karyotype, burdening clinicians with the decision to assess whether such tests are meaningful for the infertile male patient. These assess...

Descripción completa

Detalles Bibliográficos
Autores principales: Kalantari, Hamid, Sabbaghian, Marjan, Vogiatzi, Paraskevi, Rambhatla, Amarnath, Agarwal, Ashok, Colpi, Giovanni M., Sadighi Gilani, Mohammad Ali
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Korean Society for Sexual Medicine and Andrology 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10307663/
https://www.ncbi.nlm.nih.gov/pubmed/36593709
http://dx.doi.org/10.5534/wjmh.220089
_version_ 1785066082683322368
author Kalantari, Hamid
Sabbaghian, Marjan
Vogiatzi, Paraskevi
Rambhatla, Amarnath
Agarwal, Ashok
Colpi, Giovanni M.
Sadighi Gilani, Mohammad Ali
author_facet Kalantari, Hamid
Sabbaghian, Marjan
Vogiatzi, Paraskevi
Rambhatla, Amarnath
Agarwal, Ashok
Colpi, Giovanni M.
Sadighi Gilani, Mohammad Ali
author_sort Kalantari, Hamid
collection PubMed
description PURPOSE: Despite all past efforts, the current guidelines are not explicit enough regarding the indications for performing azoospermia factor (AZF) screening and karyotype, burdening clinicians with the decision to assess whether such tests are meaningful for the infertile male patient. These assessments can be costly and it is up to the healthcare practitioner to decide which are necessary and to weigh the benefits against economic/psychological harm. The aim of this study is to address such gaps and provide update on current management options for this group of patients. MATERIALS AND METHODS: To address such gaps in male infertility management and to elucidate whether AZF screening is indicated in individuals who concomitantly harbor chromosomal abnormalities we conducted a retrospective cohort analysis of 10,388 consecutive patients with non-obstructive azoospermia (NOA) and severe oligozoospermia. RESULTS: Previously, it has been suggested that all NOA cases with chromosomal defects, except males with 46,XY/45,X karyotype, have no indication for AZF screening. Our findings revealed that cases carrying the following chromosomal abnormalities inv(Y)(p11.2q12); idic(Y)(q11.2); 46,XY,r(Y); idic(Y)(p11.2) and der(Y;Autosome) (76/169; 44.9%; 95% CI, 37.7–52.5) should also be referred for AZF deletion screening. Here, we also report the correlation between sperm count and AZF deletions as a secondary outcome. In accordance with previously reported data from North America and Europe, our data revealed that only 1% of cases with >1×10(6) sperm/mL had Y chromosome microdeletions (YCMs). CONCLUSIONS: In the era of assisted reproduction, finding cost-minimization strategies in infertility clinics without affecting the quality of diagnosis is becoming one of the top prioritized topics for future research. From a diagnostic viewpoint, the results reflect a need to reconsider the different karyotype presentations and the sperm count thresholds in male infertility guidelines as indicators for YCM screening during an infertility evaluation.
format Online
Article
Text
id pubmed-10307663
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Korean Society for Sexual Medicine and Andrology
record_format MEDLINE/PubMed
spelling pubmed-103076632023-07-01 Bridging the Gap between AZF Microdeletions and Karyotype: Twelve Years’ Experience of an Infertility Center Kalantari, Hamid Sabbaghian, Marjan Vogiatzi, Paraskevi Rambhatla, Amarnath Agarwal, Ashok Colpi, Giovanni M. Sadighi Gilani, Mohammad Ali World J Mens Health Original Article PURPOSE: Despite all past efforts, the current guidelines are not explicit enough regarding the indications for performing azoospermia factor (AZF) screening and karyotype, burdening clinicians with the decision to assess whether such tests are meaningful for the infertile male patient. These assessments can be costly and it is up to the healthcare practitioner to decide which are necessary and to weigh the benefits against economic/psychological harm. The aim of this study is to address such gaps and provide update on current management options for this group of patients. MATERIALS AND METHODS: To address such gaps in male infertility management and to elucidate whether AZF screening is indicated in individuals who concomitantly harbor chromosomal abnormalities we conducted a retrospective cohort analysis of 10,388 consecutive patients with non-obstructive azoospermia (NOA) and severe oligozoospermia. RESULTS: Previously, it has been suggested that all NOA cases with chromosomal defects, except males with 46,XY/45,X karyotype, have no indication for AZF screening. Our findings revealed that cases carrying the following chromosomal abnormalities inv(Y)(p11.2q12); idic(Y)(q11.2); 46,XY,r(Y); idic(Y)(p11.2) and der(Y;Autosome) (76/169; 44.9%; 95% CI, 37.7–52.5) should also be referred for AZF deletion screening. Here, we also report the correlation between sperm count and AZF deletions as a secondary outcome. In accordance with previously reported data from North America and Europe, our data revealed that only 1% of cases with >1×10(6) sperm/mL had Y chromosome microdeletions (YCMs). CONCLUSIONS: In the era of assisted reproduction, finding cost-minimization strategies in infertility clinics without affecting the quality of diagnosis is becoming one of the top prioritized topics for future research. From a diagnostic viewpoint, the results reflect a need to reconsider the different karyotype presentations and the sperm count thresholds in male infertility guidelines as indicators for YCM screening during an infertility evaluation. Korean Society for Sexual Medicine and Andrology 2023-07 2023-01-01 /pmc/articles/PMC10307663/ /pubmed/36593709 http://dx.doi.org/10.5534/wjmh.220089 Text en Copyright © 2023 Korean Society for Sexual Medicine and Andrology https://creativecommons.org/licenses/by-nc/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0 (https://creativecommons.org/licenses/by-nc/4.0/) ) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Original Article
Kalantari, Hamid
Sabbaghian, Marjan
Vogiatzi, Paraskevi
Rambhatla, Amarnath
Agarwal, Ashok
Colpi, Giovanni M.
Sadighi Gilani, Mohammad Ali
Bridging the Gap between AZF Microdeletions and Karyotype: Twelve Years’ Experience of an Infertility Center
title Bridging the Gap between AZF Microdeletions and Karyotype: Twelve Years’ Experience of an Infertility Center
title_full Bridging the Gap between AZF Microdeletions and Karyotype: Twelve Years’ Experience of an Infertility Center
title_fullStr Bridging the Gap between AZF Microdeletions and Karyotype: Twelve Years’ Experience of an Infertility Center
title_full_unstemmed Bridging the Gap between AZF Microdeletions and Karyotype: Twelve Years’ Experience of an Infertility Center
title_short Bridging the Gap between AZF Microdeletions and Karyotype: Twelve Years’ Experience of an Infertility Center
title_sort bridging the gap between azf microdeletions and karyotype: twelve years’ experience of an infertility center
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10307663/
https://www.ncbi.nlm.nih.gov/pubmed/36593709
http://dx.doi.org/10.5534/wjmh.220089
work_keys_str_mv AT kalantarihamid bridgingthegapbetweenazfmicrodeletionsandkaryotypetwelveyearsexperienceofaninfertilitycenter
AT sabbaghianmarjan bridgingthegapbetweenazfmicrodeletionsandkaryotypetwelveyearsexperienceofaninfertilitycenter
AT vogiatziparaskevi bridgingthegapbetweenazfmicrodeletionsandkaryotypetwelveyearsexperienceofaninfertilitycenter
AT rambhatlaamarnath bridgingthegapbetweenazfmicrodeletionsandkaryotypetwelveyearsexperienceofaninfertilitycenter
AT agarwalashok bridgingthegapbetweenazfmicrodeletionsandkaryotypetwelveyearsexperienceofaninfertilitycenter
AT colpigiovannim bridgingthegapbetweenazfmicrodeletionsandkaryotypetwelveyearsexperienceofaninfertilitycenter
AT sadighigilanimohammadali bridgingthegapbetweenazfmicrodeletionsandkaryotypetwelveyearsexperienceofaninfertilitycenter